|
Synonyms: AGEN-2034 | AGEN2034 | AGEN2034w [6]
Compound class:
Antibody
Comment: Balstilimab (AGEN2034) is an anti-PD-1 checkpoint inhibitor monoclonal antibody. Peptide sequences for the heavy and light chains of balstilimab are claimed in patent US10323091B2 [6], nominally for IgG4 antibody AGEN2034w.
|
| No information available. |
Summary of Clinical Use ![]() |
| Dual treatment with balstilimab and botensilimab (AGEN-11810) is being investigated in advanced solid tumours, with a focus on treatment-refractory tumours, and those that are microsatellite-stable with low immunogenicity [1,3-5,7]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06346197 | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | Phase 3 Interventional | Centre Leon Berard | ||
| NCT06279130 | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations | Phase 2/Phase 3 Interventional | The Netherlands Cancer Institute | ||
| NCT06322108 | Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) | Phase 2 Interventional | Immune Oncology Research Institute | ||
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma | Phase 3 Interventional | Canadian Cancer Trials Group | The BATTMAN study was terminated in mid-2026 as the developer changed focus away from microsatellite stable metastatic colorectal cancer and towards microsatellite stable colon cancer. | |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | Phase 1 Interventional | Agenus Inc. | 2 | |